Literature DB >> 6869478

Fluorouracil therapy for proliferative vitreoretinopathy after vitrectomy.

W H Stern, G P Lewis, P A Erickson, C J Guerin, D H Anderson, S K Fisher, J J O'Donnell.   

Abstract

Fluorouracil effectively inhibits epiretinal membrane formation and traction retinal detachment after vitrectomy surgery. When 0.5 mg of fluorouracil was administered intraocularly every 24 hours for seven days, traction retinal detachment two weeks after the intraocular injection of 200,000 cultured retinal pigment epithelial cells occurred in 12 of 12 control eyes but in only six of 14 eyes treated with fluorouracil (P less than .001). Four weeks after cell injection, eight of 12 eyes treated with fluorouracil had traction retinal detachments whereas 12 of 12 control eyes did (P less than .001). The height of the traction retinal detachment four weeks after intraocular injection of 200,000 cultured retinal pigment epithelial cells was reduced 50% in eyes treated with 0.5 mg of fluorouracil every 24 hours for seven days compared to control eyes (P less than .001). When the number of injected retinal pigment epithelial cells was increased to 400,000 cells and 1.25 mg of fluorouracil was administered intraocularly every 24 hours for seven days, traction retinal detachment two weeks after injection occurred in 15 of 15 eyes in the control group but in none of ten eyes in the treated group. Four weeks after cell injection, eight of eight eyes in the control group and five of five eyes in the fluorouracil-treated group had detachments and the mean height of the detachments in the two groups was equal. Autoradiography of the epiretinal membranes in eyes injected with 200,000 cultured retinal pigment epithelial cells and labeled for two hours with tritiated thymidine showed that 0.8% of the epiretinal cell nuclei were labeled two weeks after cell injection but that no labeled cells were present in the fluorouracil-treated eyes. Tritiated thymidine labeling of epiretinal cells in the fluorouracil-treated eyes was first noted three weeks after the cell injection. The presence of tritiated thymidine labeling in the fluorouracil-treated eyes correlated with an increase in the number of epiretinal cells and an increase in the incidence of traction retinal detachment.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6869478     DOI: 10.1016/0002-9394(83)90452-x

Source DB:  PubMed          Journal:  Am J Ophthalmol        ISSN: 0002-9394            Impact factor:   5.258


  14 in total

1.  Computer simulation of convective and diffusive transport of controlled-release drugs in the vitreous humor.

Authors:  Matthew S Stay; Jing Xu; Theodore W Randolph; Victor H Barocas
Journal:  Pharm Res       Date:  2003-01       Impact factor: 4.200

2.  The effect of X-ray irradiation on human retinal pigment epithelial cell proliferation.

Authors:  T Ohuchi; S Kuriyama; N Yoshimura; Y Honda; M Hiraoka; M Abe
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  1991       Impact factor: 3.117

3.  The use of a liposome-encapsulated 5-fluoroorotate for glaucoma surgery: I. Animal studies.

Authors:  J A Alvarado
Journal:  Trans Am Ophthalmol Soc       Date:  1989

4.  Evaluation of 5-fluorouracil released from a foldable capsular vitreous body in vitro and in vivo.

Authors:  Haihua Zheng; Zhimin Wang; Peijuan Wang; Yaqin Liu; Zhaoxin Jiang; Qianying Gao
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2011-11-27       Impact factor: 3.117

Review 5.  Proliferative vitreoretinopathy: pathobiology, surgical management, and adjunctive treatment.

Authors:  D G Charteris
Journal:  Br J Ophthalmol       Date:  1995-10       Impact factor: 4.638

6.  Specific role of lymphatic marker podoplanin in retinal pigment epithelial cells.

Authors:  S Grimaldo; M Garcia; H Zhang; L Chen
Journal:  Lymphology       Date:  2010-09       Impact factor: 1.286

7.  Permeability and diffusion in vitreous humor: implications for drug delivery.

Authors:  J Xu; J J Heys; V H Barocas; T W Randolph
Journal:  Pharm Res       Date:  2000-06       Impact factor: 4.200

8.  Daunorubicin treatment in a refined experimental model of proliferative vitreoretinopathy.

Authors:  J A Khawly; P Saloupis; D L Hatchell; R Machemer
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  1991       Impact factor: 3.117

9.  Experimental intravitreal proliferation and neovascularization in the cynomolgus monkey.

Authors:  P Algvere; B Martini
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  1986       Impact factor: 3.117

10.  Extended retinal tamponade in the treatment of retinal detachment with proliferative vitreoretinopathy.

Authors:  W H Stern; R N Johnson; A R Irvine; M E Barricks; B S Boyden; G F Hilton; L I Lonn; A Schwartz
Journal:  Br J Ophthalmol       Date:  1986-12       Impact factor: 4.638

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.